HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Objectives: To evaluate the utility of novel serum tumor markers, HE4 and mesothelin either alone or in combination with CA125 in diagnosis and early detection of ovarian carcinoma in patients with pelvic masses.

Subjects And Methods: Sera were obtained preoperatively from 65 women underwent surgery for a pelvic mass and 25 age- and menopausal status-matched healthy women. All samples were analyzed for levels of CA125, HE4, and mesothelin by serum based immunoassays and patients results were compared to final pathology findings.